



October 30, 2017

BSE Limited
Floor 25, P. J. Towers
Dalal Street, Fort
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 051

Dear Sirs,


Sub.: Submission of copies of published Unaudited Consolidated Financial Results

In continuation of our letter dated October 28, 2017, we enclose the copies of the Unaudited Consolidated Financial Results for the quarter ended September 30, 2017 published on October 29, 2017 in Financial Express (English) and HINDUSTAN (Hindi).

This is for information and records.

Thanking you,

Yours faithfully,
For Jubilant Life Sciences Limited


Rajiv Shah
Company Secretary

Encl.: as above

A Jubilant Bhartia Company

OUR VALUES



Jubilant Life Sciences Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubl.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223,
UP, India
CIN : L24116UP1978PLC004624

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2017 (₹ in Lakhs)

Particulars	Standalone				
	Quarter ended			Year to date	
	Sep-17	Jun-17	Sep-16	Sep-17	Sep-16
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
Total Revenue	373.42	921.60	678.53	1,295.02	1,572.13
Loss for the period (before Tax and Exceptional items)	(859.73)	(592.66)	(329.26)	(1,452.39)	(492.39)
Loss for the period before tax (after Exceptional items)	(859.73)	(1,604.07)	(379.64)	(2,463.80)	(542.77)
Loss for the period after Tax (after Exceptional items)	(859.73)	(1,604.07)	(263.34)	(2,463.80)	(403.69)
Total Loss after Comprehensive Income (after tax)	(858.12)	(1,623.15)	(264.24)	(2,481.27)	(405.48)
Equity Share Capital	3,900.00	3,900.00	3,740.00	3,900.00	3,740.00
Earning Per Share (of ₹ 2/- each)					
Basic	(0.44)	(0.83)	(0.14)	(1.27)	(0.22)
Diluted	(0.44)	(0.83)	(0.14)	(1.27)	(0.22)

Note : The above is extract of detailed format of Statement of Standalone Unaudited Financial Results for the Quarter and Half Year ended September 30, 2017 filed with the stock exchange under regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (LODR).

The full format of Quarterly and Half - yearly Results is available in the Company's website www.shivacement.com and on the website of stock exchange www.bseindia.com

For & on behalf of the Board of Directors,

Date : October 27, 2017
Place : Mumbai

Manoj Kumar Rustagi
Whole Time Director



सेंट्रल बैंक ऑफ इंडिया
Central Bank of India

POSSESSION NOTICE
For Movable/Immovable Properties
[(Appendix-IV) See Rule 8(I)]

1911 से आपके लिए "सेंट्रल" "CENTRAL" TO YOU SINCE 1911

BRANCH OFFICE: DARYAGANJ, NEW DELHI

Notice is hereby given under the Securitisation and Reconstruction of Financial Assets & Enforcement of Security Interest Act, 2002 and in exercise of powers conferred under Section 13(12) read with Rule-9 of the Security Interest (Enforcement) Rules, 2002, The Bank issued demand notices on the date mentioned against accounts and stated hereinafter calling upon them to repay the amount within sixty days from the date of receipt of said notices. The borrowers having failed to repay the amount, notice is hereby given to the borrowers and the public in general that the undersigned has taken the possession of the properties described herein below in exercise of powers conferred on him/her under section 13(4) of the said Act read with Rule 9 of the said Rules on the dates mentioned against each account. The borrower in particular and the public in general are hereby cautioned not to deal with the properties. Any dealing with the properties will be subject to the charge of Central Bank of India for the amounts and interest thereon. Details of Properties where possession had been taken is as follows:

DESCRIPTION OF IMMOVABLE PROPERTY

Name of the Borrowers & Guarantors	Description of the Property Mortgaged /Charged	Date of Demand Notice	Date of Possession	Amount O/s. As Per 13(2) Notice
BORROWERS: (1) SH. NAFEES AHMED, S/O. MOHD. ISMAIL (2) WASEEM AHMED S/O. MOHD. ISMAIL R/o. C-1410 First Floor, Khasra No.58, Gali No.8, 33 Futa Road, Kabir Nagar, Delhi-110094	All that part and parcel of the property situated at: C-1410 First Floor, Khasra No.58, Gali No.8, 33 Futa Road, Kabir Nagar, Delhi-110094. Area of Property 61 Sq.Yard Bounded by: North: Other Property South: Gali East: Road West: Other Property	31.07.2017	24.10.2017	Rs. 26,91,098/- Plus future interest and other charges etc. thereon
		31.07.2017	24.10.2017	Rs. 3,11,224/- Plus future interest and other charges etc. thereon

The Borrower's attention is invited to provisions of sub-section (8) of section 13 of the Act, in respect of time available, to redeem the secured assets.

PLACE: NEW DELHI DATE: 24.10.2017

Authorised Officer, Central Bank of India

Mumbai, October 27, 2017

Chairman and Managing Director

56866/HRV



Jubilant Life Sciences Limited

Regd. Off.: Bhartiagram, Gajraula, District Amroha - 244 223 (U.P.) | CIN : L24116UP1978PLC004624
Website: www.jubl.com | Email: investors@jubl.com | Tel: +91-5924-252353-60 | Fax: +91-5924-252352

Extract of Consolidated Unaudited Results for the Quarter and Half Year ended 30 September 2017 (₹ in Lakhs)

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30 September	30 June	30 September	30 September	30 September	31 March
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	2017	2017	2016	2017	2016	2017
Total revenue from operations	164204	159605	141934	323809	287326	600632
Net Profit before tax, exceptional and extraordinary items	16813	20321	19328	37134	41144	73764
Net Profit before tax (after exceptional and extraordinary items)	16813	20321	19328	37134	41144	73764
Net Profit after tax, exceptional and extraordinary items	12547	14371	14356	26918	30748	57462
Total comprehensive income after tax (comprising profit/(loss) for the period after tax and other comprehensive income after tax)	20563	18318	9704	38881	29599	51692
Equity share capital	1557	1557	1555	1557	1555	1557
Reserves (excluding revaluation reserve)						342047
Earnings per share of ₹ 1 each before and after extraordinary items (Not annualized)						
Basic (₹)	8.23	9.44	9.29	17.67	19.68	36.93
Diluted (₹)	8.23	9.44	9.28	17.67	19.66	36.91

1. The Company has opted to publish consolidated unaudited results for the year ending 31 March 2018. The standalone unaudited results are available under Investor Relations section of our website at www.jubl.com and under Financial Results at Corporates section of www.nseindia.com and www.bseindia.com. Key standalone financial information of the Company is as under:

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30 September	30 June	30 September	30 September	30 September	31 March
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	2017	2017	2016	2017	2016	2017
Total revenue from operations	73448	71027	60640	144475	122504	262298
Profit before tax	7827	2741	3503	10568	6718	11452
Net profit after tax	5688	2229	2412	7917	4510	7919

2. Sales/Income from operations (included in total revenue from operations) for the current period is not comparable with previous periods since the same is net of Goods and Services Tax (GST) whereas excise duty formed part of expenses in previous periods.

The comparative sales/income from operations of the Company is given below:

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30 September	30 June	30 September	30 September	30 September	31 March
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	2017	2017	2016	2017	2016	2017
Sales/Income from operations (as reported)	162138	157813	139354	319951	282890	591016
Less: Excise duty on sales	22	3975	3384	3997	6823	14489
Sales/Income from operations (net of excise duty)	162116	153838	135970	319554	276067	576527

3. During the quarter, a wholly owned subsidiary of the Company, Jubilant Pharma Limited ("JPL"), through one of its wholly owned subsidiaries has completed the acquisition of the US radiopharmacy business of Triad Isotopes, Inc. The acquisition has been funded through JPL's internal accruals. This being a business combination, basis preliminary purchase price allocation to various identifiable acquired assets and assumed liabilities, provisional goodwill of ₹ 4422 lakhs has been recognised. Results for the current quarter has been impacted by acquisition related one time cost of ₹ 811 lakhs and elimination of unrealised profit of ₹ 1108 lakhs on intra group inventory out of sales made after acquisition date which otherwise would have been considered as external sales.

4. The above consolidated unaudited results were, subjected to limited review by the Statutory Auditors of the Company, reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 28 October 2017.

5. The above is an extract of the detailed format of the consolidated unaudited results for the quarter and half year ended 30 September 2017 filed with the Stock Exchanges under Regulation 33 & 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format for the consolidated unaudited results for the quarter and half year ended 30 September 2017 is available under Investor Relations section of our website at www.jubl.com and under Financial Results at Corporates section of www.nseindia.com and www.bseindia.com.

For Jubilant Life Sciences Limited

Place : Noida
Date : 28 October 2017

Hari S. Bhartia
Co-Chairman & Managing Director